HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Lars G. Svensson Todd Dewey Eric E. Roselli William N. Anderson David Brown Bruce Lytle Michael Mack Craig Smith Permission Requests Google Scholar Articles by Svensson, L. G. Articles by Smith, C. PubMed Articles by Svensson, L. G. Articles by Smith, C. Related Collections Valve disease

---

Original Articles: Adult Cardiac

United States Feasibility Study of Transcatheter Insertion of a Stented Aortic Valve by the Left Ventricular Apex

^a Center for Aortic Surgery, Marfan Syndrome and Connective Tissue Disorders Clinic, and Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
^b Medical City Hospital, Dallas, Texas
^c Columbia Presbyterian Medical Center, New York, New York
^d Consultant, Lake Forest, California

Accepted for publication April 9, 2008.

^_* Address correspondence to Dr Svensson, Center for Aortic Surgery, Marfan and Connective Tissue Disorder Clinic, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195 (Email: svenssl{at}ccf.org).

Presented at the Forty-fourth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2008.

Background: Recent US and European registries have indicated 30% to 60% of patients with critical valvular aortic stenosis (AS) are not treated surgically, usually due to advanced age and comorbidities. We report on a Food and Drug Administration approved feasibility study of a less invasive transcatheter approach to potentially treat these high-risk patients.

Methods: Between December 2006 and February 18, 2008, 40 patients underwent transcatheter insertion of a balloon expandable stainless-steel stent with an internally mounted three-leaflet equine pericardial valve (Edwards Sapien Transcatheter Heart Valve; Edwards Lifesciences, Irvine, CA) into the aortic annulus using a transapical left ventricular insertion (TA-AVI). Patients were inoperable by conventional surgery, or extremely high risk based on Society of Thoracic Surgeons score greater than 15% or other documented risk factors.

Results: All 40 valves were successfully delivered and 35 were successfully seated. Two valves embolized and required open aortic valve replacement (AVR), and one case of severe regurgitation later required AVR. In a further two patients placed on cardiopulmonary support, one valve later embolized and one migrated. There were 7 (17.5%) deaths within 30 days, and a further 2 (5%) deaths before discharge at 42 and 72 days. There were no immediate postoperative strokes after successful deployment. Valve area improved from 0.62 cm² (SD of 0.13) to 1.61 cm² (SD 0.37) at 30 days (p = <0.0001), with mean perivalvular regurgitation of 1.19 (SD 0.80). Mean follow-up was 143 days (SD 166 days) with 6 further deaths from comorbid disease, none valve or cardiac related. The Kaplan-Meier survival was 81.8% ± 6.2% at 1 month and 71.7% ± 7.7% at 3 months.

Conclusions: Transapical insertion of a balloon expandable stented valve is feasible but carries considerable risk and will be further evaluated in the PARTNER (Placement of AoRTic traNscathetER valve) randomized trial.